Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

Individuals with high PLMs had significantly higher Fazekas and ARWMC total scores than those with a lower PLM index.

For patients with acute ischemic stroke whose symptoms began 4.5 to 24 hours earlier, alteplase is associated with a higher percentage of patients achieving a score of 0 or 1 on the modified Rankin ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, ...

THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

Some people living with chronic stress have a higher risk of stroke, according to a study published on March 5, 2025, online in Neurology, the medical journal of the American Academy of Neurology.

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.